Labcorp Holdings: The Story Has Not Changed Materially

Labcorp remains a buy consideration, leveraging a successful rollup strategy in a fragmented laboratory testing industry for steady, predictable growth.

Automation is driving cost reductions in LH’s operations.

That cost reduction helps offset healthcare pricing pressures.

With a larger scale, LH now targets single-digit growth and a total return around 10%, prioritizing predictability over rapid expansion.

Risks are low due to recurring revenue, minimal acquisition disruption, and the sector’s resilience.

This is probably one of the more predictable businesses that I follow.

The last article that I wrote on Labcorp (LH) mentioned the fact that this company was basically set up as a "rollup corporation".

It was going to grow by acquiring smaller "mom and pop" sized operations